Company profile
Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Lonimecgene Renparvovec | phase3 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05606614 | phase3 | active_not_recruiting | 2023-03-06 | 2031-06-01 | Taysha Gene Therapies, Inc. | A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study) |
| NCT06152237 | phase1_2 | active_not_recruiting | 2023-12-12 | 2028-11-02 | Taysha Gene Therapies, Inc. | Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study) |
| NCT07480564 | phase3 | active_not_recruiting | 2026-05-08 | 2031-06-01 | Taysha Gene Therapies, Inc. | Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome |
FDA applications (0)
No records yet.